arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

ImmunityBio, Inc.

IBRX

$9.28 ▲ +0.83 (+9.82%) at close

14 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

ImmunityBio, Inc. faces fundamental challenges. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $8.5B

Dividend Yield —

Revenue Growth 668.3% ↘

Op. Margin -226.0%

ROIC 51.1% ↘

FCF / Share $-0.34 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 22, 2026.

14-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$113.29M

↑ +668.3% —

Net Income Profit after all expenses

$-351.40M

↑ +15.0% —

FCF / Share Free cash flow per share

$-0.34

↑ +41.2% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Financial Health ↑

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Revenue Growth YoY (%)	668.3% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+8254%)	2270.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+28282%)	159.2% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1890%)	-74.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1029%)	54.4% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+580%)	1307.0% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+16237%)	-8.5% Weak ↑ Weak Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-206%)	4.4% Caution ↑ Caution Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-44%)	2.3% Caution ↑ Caution Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-72%)	-81.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1117%)	-63.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-890%)	6.8% Fair Fair Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-15%)	—	—
EPS Growth YoY (%)	35.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	48.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-10.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-16.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-50.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	15.0% Good ↑ Good Improving Year-over-year change in net income	29.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-40.0% Weak ↑ Weak Improving Year-over-year change in net income	-20.1% Weak ↑ Weak Improving Year-over-year change in net income	-56.3% Weak ↑ Weak Improving Year-over-year change in net income	-237.2% Weak ↓ Weak Declining Year-over-year change in net income	31.6% Excellent ↑ Excellent Improving Year-over-year change in net income	0.2% Caution ↑ Caution Improving Year-over-year change in net income	20.2% Good ↑ Good Improving Year-over-year change in net income	49.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-3729.8% Weak Weak Year-over-year change in net income	-202.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	41.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	26.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	24.8% Good ↑ Good Improving Year-over-year change in free cash flow	-31.4% Weak Weak Year-over-year change in free cash flow	-72.1% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	678.6% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	150.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	0.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	77.4% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	170.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	137.8% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-0.8% Weak ↑ Weak Improving Compound annual revenue growth over 3 years	-41.6% Weak ↑ Weak Improving Compound annual revenue growth over 3 years	-58.7% Weak Weak Compound annual revenue growth over 3 years	-58.1% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	184.8% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	221.4% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	67.6% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	39.8% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	84.2% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	20.7% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	-41.7% Weak Weak Compound annual revenue growth over 5 years	-39.9% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Operating Margin (%) (%)	-226.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1607%)	—	—	—	—	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.8% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-310.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2685%)	—	—	—	—	—	—	—	—	—	—	—	-341.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2943%)	—
FCF Margin (%) (%)	-272.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Return on Invested Capital (%)	51.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	70.4% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	61.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	78.5% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	136.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	182.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-56.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-67.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-67.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-9.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-51.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-89.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-71.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-96.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-70.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-99.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-39.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-65.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	70.2% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+368%)	84.6% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+464%)	99.4% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+562%)	93.1% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+521%)	143.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+855%)	185.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1134%)	-54.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-463%)	-65.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-539%)	-44.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-394%)	-41.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-374%)	-66.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-544%)	-10.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-172%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Interest Coverage (x)	-4.21x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-3.00x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2.81x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-5.53x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-22.24x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-24.34x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3568.79x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-207.13x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-148.38x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1886.36x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-11.84x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-88.33M	$-143.43M	$-265.45M	$-104.64M	$-181.10M	$-34.91M	$-15.51M	$-16.82M	$-23.87M	$-8.08M	$-175.91M	$-59.10M	$-350.00K	$-116.00K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Revenue per Share (USD)	$0.12	$0.02	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.38	$-0.59	$-1.15	$-1.04	$-0.89	$-0.59	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.34	$-0.57	$-0.78	$-1.04	$-0.79	$-0.46	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$-0.49	$-0.57	$-0.87	$-1.06	$-0.61	$-0.31	$1.23	$1.85	$2.77	$3.58	$4.38	—	—	—
Tangible Book Value per Share (USD)	$-0.50	$-0.57	$-0.87	$-1.11	$-0.61	$-0.32	$1.23	$1.84	$2.73	$3.52	$4.29	—	—	—
Basic Weighted Avg Shares (shares)	919.86M	697.31M	508.64M	399.90M	389.23M	377.07M	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Working Capital (USD)	$253.12M	$129.64M	$235.80M	$-360.28M	$-34.65M	$43.58M	$44.20M	$61.51M	$111.59M	$192.59M	$291.39M	—	—	—
Total Equity (USD)	$-500.47M	$-489.10M	$-586.99M	$-447.33M	$-242.17M	$-119.81M	$120.68M	$146.01M	$218.84M	$293.42M	$356.00M	$57.59M	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Sales/Revenue/Turnover (USD)	$113.29M	$14.74M	$622.00K	$240.00K	$934.00K	$605.00K	$43.00K	$47.00K	$45.00K	$44.00K	$236.00K	$641.00K	$600.00K	—
Depreciation Expense (USD)	$15.53M	$17.55M	$18.51M	$18.26M	$14.24M	$12.74M	$9.01M	$9.55M	$5.57M	$3.61M	$1.47M	$36.00K	$4.00K	—
Net Income, GAAP (USD)	$-351.40M	$-413.56M	$-583.20M	$-416.57M	$-346.79M	$-221.85M	$-65.79M	$-96.23M	$-96.42M	$-120.81M	$-236.88M	$-6.18M	$-2.05M	—
Operating Cash Flow (USD)	$-304.94M	$-391.24M	$-366.76M	$-337.51M	$-274.42M	$-171.72M	$-61.36M	$-63.38M	$-48.78M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 52 quarters

ImmunityBio, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IBRX with peers